Ziyad T. Ahmed

Dr. Ziyad T. Ahmed

Sulaiman Al Rajhi Colleges, Al Bukayrīyah, Saudi Arabia
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GJGhazi I. Al Jowf
Ghazi I. Al Jowf
ZAZiyad T. Ahmed
Ziyad T. Ahmed
RRRick A. Reijnders
Rick A. Reijnders
LNLaurence de Nijs
Laurence de Nijs
LELars M.T. Eijssen
Lars M.T. Eijssen
Post-traumatic stress disorder (PTSD) can become a chronic and severely disabling condition resulting in a reduced quality of life and increased economic burden. The disorder is directly related to exposure to a traumatic event, e.g., a real or threatened injury, death, or sexual assault. Extensive research has been done on the neurobiological alterations underlying the disorder and its related phenotypes, revealing brain circuit disruption, neurotransmitter dysregulation, and hypothalamic–pituitary–adrenal (HPA) axis dysfunction. Psychotherapy remains the first-line treatment option for PTSD given its good efficacy, although pharmacotherapy can also be used as a stand-alone or in combination with psychotherapy. In order to reduce the prevalence and burden of the disorder, multilevel models of prevention have been developed to detect the disorder as early as possible and to reduce morbidity in those with established diseases. Despite the clinical grounds of diagnosis, attention is increasing to the discovery of reliable biomarkers that can predict susceptibility, aid diagnosis, or monitor treatment. Several potential biomarkers have been linked with pathophysiological changes related to PTSD, encouraging further research to identify actionable targets. This review highlights the current literature regarding the pathophysiology, disease development models, treatment modalities, and preventive models from a public health perspective, and discusses the current state of biomarker research.

GJGhazi I. Al Jowf
Ghazi I. Al Jowf
ZAZiyad T. Ahmed
Ziyad T. Ahmed
NANing An
Ning An
RRRick A. Reijnders
Rick A. Reijnders
Elena AmbrosinoElena Ambrosino
Elena Ambrosino
LELars M.T. Eijssen
Lars M.T. Eijssen
Trauma exposure is one of the most important and prevalent risk factors for mental and physical ill-health. Prolonged or excessive stress exposure increases the risk of a wide variety of mental and physical symptoms, resulting in a condition known as post-traumatic stress disorder (PTSD). The diagnosis might be challenging due to the complex pathophysiology and co-existence with other mental disorders. The prime factor for PTSD development is exposure to a stressor, which variably, along with peritraumatic conditions, affects disease progression and severity. Additionally, many factors are thought to influence the response to the stressor, and hence reshape the natural history and course of the disease. With sufficient knowledge about the disease, preventive and intervenient methods can be implemented to improve the quality of life of the patients and to limit both the medical and economic burden of the disease. This literature review provides a highlight of up-to-date literature on traumatic stress, with a focus on causes or triggers of stress, factors that influence response to stress, disease burden, and the application of the social-ecological public health model of disease prevention. In addition, it addresses therapeutic aspects, ethnic differences in traumatic stress, and future perspectives, including potential biomarkers.

13 June 2024 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
ZAZiyad T. Ahmed
Ziyad T. Ahmed
MAMaha Saad Zain Al-Abeden
Maha Saad Zain Al-Abeden
MAMohamed Ghaith Al Abdin
Mohamed Ghaith Al Abdin
MMMohamad Ayham Muqresh
Mohamad Ayham Muqresh
GJGhazi I. Al Jowf
Ghazi I. Al Jowf
KHKhawaja Husnain Haider
Khawaja Husnain Haider
Background: Mesenchymal stem cells (MSCs) have emerged as living biodrugs for myocardial repair and regeneration. Recent randomized controlled trials (RCTs) have reported that MSC-based therapy is safe and effective in heart failure patients; however, its dose-response relationship has yet to be established. We aimed to determine the optimal MSC dose for treating HF patients with reduced ejection fraction (EF) (HFrEF). Methods: The preferred reporting items for systematic reviews and meta-analyses (PRISMA) and Cochrane Handbook guidelines were followed. Four databases and registries, i.e., PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other websites, were searched for RCTs. Eleven RCTs with 1098 participants (treatment group, n = 606; control group, n = 492) were selected based on our inclusion/exclusion criteria. Two independent assessors extracted the data and performed quality assessments. The data from all eligible studies were plotted for death, major adverse cardiac events (MACE), left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and 6-minute walk distance (6-MWD) as safety, efficacy, and performance parameters. For dose-escalation assessment, studies were categorized as low-dose (< 100 million cells) or high-dose (≥ 100 million cells). Results: MSC-based treatment is safe across low and high doses, with nonsignificant effects. However, low-dose treatment had a more significant protective effect than high-dose treatment. Subgroup analysis revealed the superiority of low-dose treatment in improving LVEF by 3.01% (95% CI; 0.65–5.38%) compared with high-dose treatment (-0.48%; 95% CI; -2.14-1.18). MSC treatment significantly improved the 6-MWD by 26.74 m (95% CI; 3.74–49.74 m) in the low-dose treatment group and by 36.73 m (95% CI; 6.74–66.72 m) in the high-dose treatment group. The exclusion of studies using ADRCs resulted in better safety and a significant improvement in LVEF from low- and high-dose MSC treatment. Conclusion: Low-dose MSC treatment was safe and superior to high-dose treatment in restoring efficacy and functional outcomes in heart failure patients, and further analysis in a larger patient group is warranted.

31 October 2022 in Journal of Clinical and Translational Research
Verified
Journal Article
Closed access
ZAZiyad T. Ahmed
Ziyad T. Ahmed
MAMaher T. Al-Omar
Maher T. Al-Omar
MAMahmoud T. Alnajjar
Mahmoud T. Alnajjar
ZAZiyad T. Ahmed
Ziyad T. Ahmed
FSFaris M. I. Salaas
Faris M. I. Salaas
KHKhawaja H. Haider
Khawaja H. Haider
Background: Endothelial progenitor cells (EPCs) have been well-studied for their differentiation potential and paracrine activity in vitro and in experimental animal studies. EPCs are the precursors of endothelial cells (ECs) and a rich source of proangiogenic factors, and hence, possess enormous potential to treat ischemic heart via myocardial angiogenesis. Their proven safety and efficacy observed during the pre-clinical and clinical studies have portrayed them as a near-ideal cell type for cell-based therapy of ischemic heart disease. In response to the chemical cues from the ischemic heart, EPCs from the bone marrow and peripheral circulation home-in to the ischemic myocardium and participate in the intrinsic repair process at the molecular and cellular levels via paracrine activity and by undergoing EC differentiation. EPCs also release small extracellular vesicles (sEVs) loaded with bioactive molecules as part of their paracrine activity for intercellular communication to participate in the reparative process in the heart. Aim: This literature review is based on the published data regarding the characteristic features of EPCs-derived sEVs and their proteomic and genomic payload, besides facilitating safe and effective repair of the ischemic myocardium. In light of the encouraging published data, translational and clinical assessment of EPCs-derived sEVs is warranted. We report the recent experimental animal studies and their findings using EPCs-derived sEVs on cardiac angiogenesis and preservation of cardiac function. Relevance for patients: With the promising results from preclinical studies, clinical trials should be conducted to assess the clinical utility of EPCs-derived sEVs in the treatment of the ischemic myocardium.

12 April 2025 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
OAOmar T. F. Ahmed
Omar T. F. Ahmed
ZAZiyad T. Ahmed
Ziyad T. Ahmed
ADAbdulrahman W. Dairi
Abdulrahman W. Dairi
MAMaha Saad Zain Al-Abeden
Maha Saad Zain Al-Abeden
MAMohammed H. Alkahlot
Mohammed H. Alkahlot
KHKhawaja Husnain Haider
Khawaja Husnain Haider
Recent randomized controlled trials have consistently demonstrated the safety and potential efficacy of MSC therapy for heart failure patients. This study delves into mesenchymal stem cells’ promising potential, offering a beacon of hope for the future of heart failure treatment with reduced ejection fraction (HFrEF). We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for this systematic review and meta-analysis. We searched four databases and registers for RCTs, including PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other relevant websites. We then selected thirteen RCTs with 1184 participants based on our pre-defined inclusion/exclusion criteria. Two independent assessors extracted the data and performed a quality assessment. The data were then plotted for various outcomes, including death, hospitalization, major adverse cardiac events, pump function parameters, and 6-min walk distance. The safety of MSC-based treatment has been consistently demonstrated with MSCs from autologous (AutoMSCs) and allogeneic (AlloMSCs) sources. This reassuring finding underscores the reliability of MSC-based therapy irrespective of their source. However, AutoMSCs showed a trend toward greater protective benefits. Subgroup analysis revealed no significant differences between AutoMSCs and AlloMSCs in improving LVEF; 0.86% (95% CI − 1.21–2.94%) for AlloMSCs versus 2.17% (− 0.48%; 95% CI − 1.33–5.67%) for AutoMSCs. AlloMSCs significantly reduced end-diastolic volume (LVEDV) by − 2.08 mL (95% CI − 3.52—0.64 mL). Only AlloMSCs significantly improved 6-min walking distance (6-MWD); 31.88 m (95% CI 5.03–58.74 m) for AlloMSCs versus 31.71 m (95% CI − 8.91–71.25 m) for AutoMSCs. The exclusion of studies using adipose-derived cells resulted in even better safety and a significant improvement in LVEF for AlloMSCs treatment. Our findings suggest that AlloMSCs are at par with AutoMSCs in improving functional outcomes in heart failure patients. This underscores the need for future investigations in a larger patient cohort, emphasizing the urgency and importance of further research to fully understand the potential of MSCs in treating heart failure.

18 August 2023
Verified
Book Chapter
Closed access
PDF file
ZAZiyad T. Ahmed
Ziyad T. Ahmed
MAMohammed H. Alkahlot
Mohammed H. Alkahlot
KHKhawaja Husnain Haider
Khawaja Husnain Haider